Serious side effects are the same as those for other short-acting insulin analogs, including hypoglycemia, severe allergic reactions, and hypokalemia. Other common side effects may include ...

The FDA approved its short-acting insulin, Fiasp (insulin aspart injection) in September, and its long-acting insulin Tresiba (insulin degludec) got US approval late last year. [caption id ...

To mimic physiological insulin release, both long-acting and short-acting insulin preparations are needed. After decades of optimizations to develop longer-acting insulin preparations to reduce ...